阿帕他胺治疗中国前列腺癌患者真实世界的临床观察  

Real-world clinical observation of apalutamide in Chinese patients with prostate cancer

作　　者：姜婧琦 贺大林[2] 李磊[2] 秦卫军 种铁[4] 杨增悦 文彬[6] 陈鹏[7] 李恒平[8] 周逢海 尹永生[8] 张波 王玉杰[10] 程永毅[11] 李军[12] 王志平[1] JIANG Jingqi;HE Dalin;LI Lei;QIN Weijun;ZHONG Tie;YANG Zengyue;WEN Bin;CHEN Peng;LI Hengping;ZHOU Fenghai;YIN Yongsheng;ZHANG Bo;WANG Yujie;CHENG Yongyi;LI Jun;WANG Zhiping(Department of Urology,The Second Hospital of Lanzhou University,Gansu Provincial Key Laboratory of Urological Disease Research,Lanzhou 730000;Department of Urology,The First Affiliated Hospital of Xi’an Jiaotong University,Xi’an 710000;Department of Urology,XijingHospital,The Air Force Medical University,Xi’an 710000;Department of Urology,The Second Affiliated Hospital of Xi’an Jiaotong University,Xi’an 710000;Department of Urology,Hospital of Xi’an International Medical Center,Xi’an 710000;Department of Urology,People’s Hospital of Xinjiang Autonomous Region,Urumqi 830000;Department of Urology,Affiliated Cancer Hospital of Xinjiang Medical University,Urumqi 830000;Department of Urology,Gansu Provincial People’s Hospital,Lanzhou 730000;Department of Urology,Tangdu Hospital,The Air Force Medical University,Xi’an 710000;Department of Urology,The First Affiliated Hospital of Xinjiang Medical University,Urumqi 830000;Department of Urology,Shanxi Provincial People’s Hospital,Xi’an 710000;Department of Urology,Gansu Provincial Cancer Hospital,Lanzhou 730000,China)

机构地区：[1]兰州大学第二医院泌尿外科,甘肃省泌尿系疾病研究重点实验室,甘肃兰州730000 [2]西安交通大学医学院第一附属医院泌尿外科,陕西西安710000 [3]空军军医大学西京医院泌尿外科,陕西西安710000 [4]西安交通大学医学院第二附属医院泌尿外科,陕西西安710000 [5]西安国际医学中心泌尿外科,陕西西安710000 [6]新疆维吾尔自治区人民医院泌尿外科,新疆乌鲁木齐830000 [7]新疆医科大学附属肿瘤医院泌尿外科,新疆乌鲁木齐830000 [8]甘肃省人民医院泌尿外科,甘肃兰州730000 [9]空军军医大学唐都医院泌尿外科,陕西西安710000 [10]新疆医科大学第一附属医院泌尿外科,新疆乌鲁木齐830000 [11]陕西省人民医院泌尿外科,陕西西安710000 [12]甘肃省肿瘤医院泌尿外科,甘肃兰州730000

出　　处：《现代泌尿外科杂志》2022年第10期851-855,共5页Journal of Modern Urology

摘　　要：目的评估阿帕他胺治疗中国西北前列腺癌(PCa)患者的前列腺特异性抗原(PSA)反应和疾病控制效果。方法这项回顾性临床研究包括2020年4月-2021年10月期间在中国西北地区接受阿帕他胺治疗的37例被诊断为PCa的患者的临床资料。根据疾病进展阶段对患者进行分层,主要观察指标为用药后患者的血清PSA反应,次要观察指标为影像学反应。结果37例患者接受阿帕他胺联合雄激素剥夺(ADT)治疗后,所有局限PCa和转移性激素敏感性前列腺癌(mHSPC)患者PSA均呈持续下降趋势,转移性去势抵抗性前列腺癌(mCRPC)中有6例(42.9%)患者PSA呈下降趋势。影像学随访结果提示,8例(88.9%)mHSPC和1例(25%)mCRPC患者分别在治疗3、6个月后观察到骨转移减少。结论真实世界环境中阿帕他胺显示出显著的PSA反应率以及影像学益处,为PCa患者的治疗提供了新思路。Objective To evaluate the prostate-specific antigen(PSA)response and disease control effect of apalutamide in patients with prostate cancer(PCa)in northwest China.Methods The retrospective clinical study included 37 patients diagnosed with PCa who were treated with apalutamide during Apr.2020 and Oct.2021.Patients were stratified according to the stage of disease progression.The main and secondary observation index were serum PSA response after medication and imaging findings.Results After medication with apalutamide plus androgen deprivation(ADT),PSA in all patients with localized PCa and metastatic hormone-sensitive prostate cancer(mHSPC)showed a continuous downward trend,and PSA in 6 patients(42.9%)with metastatic castration-resistant prostate cancer(mCRPC)also showed a downward trend.Follow-up radiography showed that 8(88.9%)mHSPC and 1(25%)mCRPC cases had reduced bone metastases at 3 and 6 months,respectively.Conclusion Apalutamide has shown significant PSA response rates and radiological benefits in real-world settings,and provides a new thought for the treatment of PCa patients.

关 键 词：真实世界 中国西北 前列腺癌 阿帕他胺 前列腺特异性抗原 影像学 

分 类 号：R453[医药卫生—治疗学]